BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
BARD1 Life Sciences Ltd was established in June 2016, after acquiring BARD1AG SA and listing on the Australian Stock Exchange as ASX:BD1. Our research activities are currently performed under a research contract at the University of Geneva (UNIGE).
The BARD1 technology was originally developed by a leading research team at the University of Geneva (UNIGE) and University Hospital of Geneva (HUG). The research team, led by internationally renowned scientist Dr Irmgard Irminger-Finger, cloned the BARD1 gene and determined its biological function, pioneered translational research validating BARD1 autoantibodies as an important biomarker for cancer, built a solid intellectual property portfolio, established collaborations worldwide and received multiple grants to advance the commercialisation of the BARD1 technology for diagnostic and therapeutic uses in cancer.
BARD1’s business strategy is to focus on leveraging its BARD1 Technology to develop diagnostic tests for early detection of cancer when it can be potentially cured. BARD1 plans to develop a portfolio of non-invasive diagnostic tests for early detection, diagnosis or monitoring of cancer, conduct clinical validation studies to demonstrate the performance of its BARD1 Tests and enable medical device marketing, and then commercialise its products through licensing its diagnostic tests to clinical laboratory, major diagnostic or biopharmaceutical partners in the USA, Europe and Asia. Importantly, BARD1 will strive to create value for ASX:BD1 shareholders.